"We are off to a strong start this year, delivering $28.4 million in ACV, a 12% increase compared to Q1 last year" (CEO, President & Director Ramy Farid), while adding that "Drug discovery revenue of ...
Schrodinger Inc (NASDAQ:SDGR) is among the best medical AI stocks to buy now. Schrodinger Inc (NASDAQ:SDGR)’s management presented at the 2026 KeyBanc Capital Markets Healthcare Forum on March 17. The ...
Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results